AI assistant
Sending…
Neurogene Inc. — Director's Dealing 2019
Aug 12, 2019
33497_dirs_2019-08-12_86ddfdcc-35ff-48a0-9ba2-38b5c6a27aca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Neoleukin Therapeutics, Inc. (NLTX)
CIK: 0001404644
Period of Report: 2019-08-08
Reporting Person: Williams Lewis T (Director)
More from Neurogene Inc.
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 20
Annual Report
2026
Apr 16
Proxy Solicitation & Information Statement
2026
Apr 16
Regulatory Filings
2026
Mar 24
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 17
Director's Dealing
2026
Mar 3
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 24